Table 1 Descriptive data of participants
Variable | Final participants (n = 53) | ||
Mean age (SD) [years] | 38.42 (8.77) | ||
Sex (female:male) | 45:8 | ||
Comorbidity (%) | None: 43 (81.13) HTN/CV: 3 (5.66) Hypothyroidism: 2 (3.77) DM: 4 (7.55) | ||
Median MS duration (IQR) [years] | 10 (13) | ||
DMT (%) | No DMT: 3 (5.66) IFNs: 4 (7.54) DMF: 21 (39.62) TFN: 1 (1.89) GA: 1 (1.89) FNG: 12 (22.64) RTX: 9 (16.98) AZA: 2 (3.77) | ||
COVID-19 diagnosis type (%) | RT-PCR: 30 (56.60) CT: 14 (26.42) Both: 9 (16.98) | ||
COVID-19 severity (%) | No hospitalization: 47 (88.68) Hospitalization: 6 (11.32) | ||
Mean post-COVID-19 follow-up (SD) [months] | 10.58 (2.48) | ||
Outcome | Pre-COVID-19 period endpoint | Post-COVID-19 period endpoint | P value |
Median EDSS (IQR) | 1.5 (1) | 1.5 (1) | 0.08* |
Number of patients with probable disability progression (%) | 10 (18.87) | 3 (5.66) | 0.04** |
Number of patients experiencing relapses (%) | 16 (30.19) | 11 (20.75) | 0.30** |